Table 5.

Multivariable association of severity of AKI and change (fold increase) in level of urine protein-to-creatinine ratio overall and analyses that exclude receipt of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or systolic BP level

ComparisonsFull ModelModel Excluding Receipt of ACE-I/ARBModel Excluding Systolic BP Level
Relative Risk (95% CI)P ValueRelative Risk (95% CI)P ValueRelative Risk (95% CI)P Value
AKI stage 1 between study visits (versus no AKI)1.06 (0.97 to 1.16)0.221.06 (0.97 to 1.16)0.211.04 (0.95 to 1.14)0.35
AKI stage 2 between study visits (versus no AKI)1.01 (0.89 to 1.15)0.881.01 (0.88 to 1.15)0.920.99 (0.87 to 1.13)0.89
AKI stage 3 between study visits (versus no AKI)1.24 (1.09 to 1.40)<0.0011.25 (1.10 to 1.42)<0.0011.21 (1.06 to 1.37)<0.01
  • ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; 95% CI, 95% confidence interval.